comparemela.com

Latest Breaking News On - Praxis precision medicines - Page 4 : comparemela.com

Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at Robert W. Baird

Praxis Precision Medicines (NASDAQ:PRAX) Now Covered by Analysts at Robert W. Baird
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Robertw-baird
Connor-clark-lunn-investment-management-ltd
Praxis-precision-medicines-inc
Jefferies-financial-group
Simplex-trading
York-mellon-corp
Citigroup-inc
Jump-financial
Praxis-precision-medicines
Free-report
Financial-group

Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls

Short Interest in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Expands By 77.1%

Short Interest in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Expands By 77.1%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Windmill-hill-asset-management-ltd
Nasdaq
Jefferies-financial-group
Wealth-advisors
Victory-capital-management-inc
Simplex-trading
Praxis-precision-medicines-inc
Praxis-precision-medicines
Get-free-report
Capital-management
Hill-asset-management-ltd

HC Wainwright Reiterates "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX)

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $105.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 91.61% from the company’s previous close. PRAX […]

Connor-clark-lunn-investment-management-ltd
Nasdaq
Praxis-precision-medicines-inc
Asset-management-inc
Jefferies-financial-group
Silverarc-capital-management
Jump-financial
York-mellon-corp
Praxis-precision-medicines
Get-free-report
Financial-group

Praxis Precision Medicines' (PRAX) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Praxis Precision Medicines (NASDAQ:PRAX – Free Report) in a research note issued to investors on Friday morning, Benzinga reports. They currently have a $105.00 price objective on the stock. Other analysts have also issued reports about the company. Wedbush boosted their price objective on Praxis Precision […]

Acuta-capital-partners
Praxis-precision-medicines-inc
Citigroup-inc
Silverarc-capital-management
Jefferies-financial-group
Asset-management-inc
Praxis-precision-medicines
Free-report
Financial-group
Precision-medicines
Get-free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.